Lonza 4D-Nucleofector LV Unit for non-viral primary T-cell transfection

Saturday, 10 September, 2016 | Supplied by: Capsugel Australia Pty Ltd


Lonza has announced its 4D-Nucleofector LV Unit, the latest addition to the 4D-Nucleofector System, which expands non-viral primary T-cell transfection to a closed, larger-scale format. Nucleofector Technology is said to improve on traditional electroporation methods to deliver enhanced transfection efficiencies while using less substrate and with only a moderate impact on cell viability. It is suitable for scientists working with hard-to-transfect cell types, like primary blood cells or stem cells.

The system was designed with the scientist in mind, so transfection protocols established on the existing smaller-scale unit can be smoothly transferred to the large-scale unit without the need for re-optimisation. The fully closed system is also suitable for use in a regulatory environment as it can be controlled by 21 CFR Part 11-compatible software. The addition of this larger-scale transfection format allows scientists to translate the results of their research applications into potential therapeutic applications.

Online: lonzabioscience.com.au
Phone: 1300 657508
Related Products

Maxwell Biosystems MaxTwo high-density microelectrode array (HD-MEA) system

The next-generation multiwell HD-MEA captures high-quality signals at subcellular resolution from...

Enzo Life Sciences PROTEOSTAT Protein refolding and aggregation sensing kit

The kit includes a comprehensive set of optimised screening reagents and conditions that...

Bio-Rad Laboratories ddPLEX ESR1 Mutation Detection Kit

The kit enables simultaneous detection, discrimination and absolute quantification of seven known...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd